Jefferies Financial Group Inc. lessened its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 22.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,876 shares of the medical instruments supplier’s stock after selling 8,869 shares during the quarter. Jefferies Financial Group Inc.’s holdings in West Pharmaceutical Services were worth $8,220,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Elyxium Wealth LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $25,000. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services during the second quarter worth approximately $25,000. Private Trust Co. NA raised its stake in shares of West Pharmaceutical Services by 156.4% during the fourth quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the last quarter. International Assets Investment Management LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $31,000. Finally, Torren Management LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth approximately $34,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.
Insiders Place Their Bets
In other news, VP Annette F. Favorite sold 2,817 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total value of $859,748.40. Following the completion of the transaction, the vice president owned 16,828 shares in the company, valued at $5,135,905.60. This trade represents a 14.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Chad Winters sold 896 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the completion of the transaction, the chief accounting officer owned 1,523 shares of the company’s stock, valued at approximately $457,920.41. This represents a 37.04% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.60% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Report on WST
West Pharmaceutical Services Stock Performance
NYSE:WST opened at $316.86 on Monday. The company has a quick ratio of 2.04, a current ratio of 2.71 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a fifty-two week low of $203.74 and a fifty-two week high of $330.88. The stock has a market cap of $22.39 billion, a PE ratio of 42.36, a price-to-earnings-growth ratio of 2.65 and a beta of 1.17. The firm’s fifty day simple moving average is $275.46 and its 200-day simple moving average is $266.26.
West Pharmaceutical Services (NYSE:WST – Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The business had revenue of $844.90 million for the quarter, compared to analysts’ expectations of $779.68 million. During the same period in the prior year, the company posted $1.45 EPS. The business’s revenue for the quarter was up 21.0% on a year-over-year basis. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. Analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.
West Pharmaceutical Services declared that its Board of Directors has authorized a share repurchase plan on Tuesday, February 17th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.6% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.
Featured Articles
- Five stocks we like better than West Pharmaceutical Services
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Free Report).
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
